Kineret (anakinra) Injection
Approval: December 18, 2020
Now Approved for: Deficiency of IL-1 Receptor Antagonist (DIRA
Xolair (omalizumab) Subcutaneous Injection
Approval: December 1, 2020
Now Approved for: Nasal Polyps
Xeomin (incobotulinumtoxinA) Injection
Approval: December 18, 2020
Now Approved for: Chronic Sialorrhea in Patients Aged 2 Years and Older
Benlysta (belimumab) Injection
Approval: December 16, 2020
Now Approved for: Adult Patients with Active Lupus Nephritis
Iclusig (ponatinib) Tablets
Approval: December 18, 2020
Now Approved for: Adult Patients with Resistant or Intolerant Chronic-Phase CML
Hetlioz (tasimelteon) Capsules
Approval: December 1, 2020
Now Approved for: Nighttime Sleep Disturbances in Smith-Magenis Syndrome
Saxenda (liraglutide) Injection
Approval: December 4, 2020
Now Approved for: Obesity in Adolescents Aged 12-17
Tagrisso (osimertinib) Tablets
Approval: December 20, 2020
Now Approved for: Early-Stage EGFR-Mutated Non-Small Cell Lung Cancer
Ocrevus (ocrelizumab) Injection
Approval: December 14, 2020
Now Approved: Shorter 2-Hour Infusion for Relapsing and Primary Progressive Multiple Sclerosis
Xpovio FDA Approval History
Approval: December 14, 2020
Now Approved for: Patients with Multiple Myeloma After At Least One Prior Therapy
Xpovio (selinexor) Tablets
Approval: December 18, 2020
Now Approved for: Patients with Multiple Myeloma After At Least One Prior Therapy
Gavreto (pralsetinib) Capsules
Approval: December 1, 2020
Now Approved for: RET-Mutant and RET Fusion-Positive Thyroid Cancers